Phaseline

Companies › Khondrion

Khondrion: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology, Infectious disease; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sonlicromanol
Mitochondrial function enhancer; CardioProtein complex I supporter
–Phase 3Mitochondrial Diseases; Post COVID ConditionSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07298005SonlicromanolPhase 2Post COVID ConditionInfectious diseaseFeb 2027
NCT06451757SonlicromanolPhase 3Mitochondrial DiseasesNeurologySep 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Green Valley (Shanghai) Pharmaceuticals CereMark Pharma Tatchempharmpreparaty, JSC Carnot Laboratories Prilenia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.